Varenicline for smoking cessation

TA123 Smoking cessation - varenicline: review decision - January 2011 information

TA123 Smoking cessation - varenicline: appendix A: review decision paper considered by the Institute's Guidance Executive

TA123 Smoking cessation - varenicline: appendix A: review decision paper considered by the Institute's Guidance Executive (PDF 87 KB)

Review Proposal - October 2010 information

Appendix A: provisional matrix of stakeholders

Appendix A: provisional matrix of stakeholders (MSWord 70 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive

Final appraisal determination information

Final appraisal determination

Final appraisal determination (PDF 108 KB)

Evaluation report

Non-manufacturer submissions

British Cardiovascular Society

British Cardiovascular Society (PDF 37 KB)

East Lancashire PCT

East Lancashire PCT (PDF 41 KB)

General Practice Airways Group

General Practice Airways Group (PDF 52 KB)

General Practice Airways Group supporting document

General Practice Airways Group supporting document (PDF 76 KB)

Roy Castle Lung Cancer Foundation

Roy Castle Lung Cancer Foundation (PDF 78 KB)

Manufacturer submission

Manufacturer submission (PDF 1.42 MB)

Clarification letters

NICE clarification letter 1

NICE clarification letter 1 (PDF 29 KB)

NICE clarification letter 2

NICE clarification letter 2 (PDF 17 KB)

Pfizer clarification letter

Pfizer clarification letter (PDF 578 KB)

Pre-meeting briefing

Pre-meeting briefing (PDF 53 KB)

Expert written personal statements

Geldard

Geldard (PDF 38 KB)

Owens

Owens (PDF 77 KB)

Smoking cessation - varenicline: evidence review group report

Smoking cessation - varenicline: Final scope

Smoking cessation - varenicline: Response to consultee and commentator comments on the draft scope

Smoking cessation - varenicline: Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Smoking cessation - varenicline: Audit criteria